Skip to content
Disclosery

CHI Advisors LLC

Follow

13F filer, CIK 1791468, NEW YORK, NY

CHI Advisors LLC reported $301,278,000 across 20 holdings for the quarter ended 2021-12-31, in a 13F-HR filed 2022-02-11. Its ten largest share positions make up 86.7% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001085146-22-000838

Period
2021-12-31
Reported value
$301M
Holdings
20
Top 10 weight
86.7%
New
1
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CMPXnew+3,023,692$9.59M
IKENA ONCOLOGY INCadded+499,756$6.27M
CGEMadded+231,879$3.58M
KEZAR LIFE SCIENCES INCadded+197,250$3.3M
ORCHARD THERAPEUTICS PLCadded+2,367,884$3.13M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
PROMETHEUS BIOSCIENCES INCreduced-1,109,816-$43.9M
REPARE THERAPEUTICS INCreduced-20,527-$433K
PRECISION BIOSCIENCES INCreduced-40,100-$297K
INOZYME PHARMA INCreduced-28,207-$192K
AKOUOS INCreduced-21,907-$186K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2021

Share positions as resolved from 13F-HR 0001085146-22-000838, largest first. % of portfolio is the value over $301,278,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PROMETHEUS BIOSCIENCES INCPROMETHEUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 1,752,243 shares 1,752,243$69.3M23%-1,109,816
REPARE THERAPEUTICS INCREPARE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 2,212,256 shares 2,212,256$46.7M15.49%-20,527
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 2,476,720 shares 2,476,720$38.2M12.68%+231,879Timeline
PLRXPLIANT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 2,569,479 shares 2,569,479$34.7M11.51%+84,755Timeline
LRMRLARIMAR THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 1,515,148 shares 1,515,148$16.3M5.43%0Timeline
VECTIVBIO HLDG AGVECTIVBIO HLDG AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 2,675,408 shares 2,675,408$13.1M4.36%+82,806
OMEGA THERAPEUTICS INCOMEGA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 1,055,882 shares 1,055,882$12M3.97%0
ONCORUS INCONCORUS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 2,106,903 shares 2,106,903$11.1M3.69%+350,924
IKENA ONCOLOGY INCIKENA ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 814,756 shares 814,756$10.2M3.39%+499,756
CMPXCOMPASS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 3,023,692 shares 3,023,692$9.59M3.18%newTimeline
ORCHARD THERAPEUTICS PLCORCHARD THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 6,449,856 shares 6,449,856$8.51M2.83%+2,367,884
AKOUOS INCAKOUOS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 836,120 shares 836,120$7.11M2.36%-21,907
INOZYME PHARMA INCINOZYME PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 892,057 shares 892,057$6.08M2.02%-28,207
KEZAR LIFE SCIENCES INCKEZAR LIFE SCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 272,250 shares 272,250$4.55M1.51%+197,250
PRECISION BIOSCIENCES INCPRECISION BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 606,629 shares 606,629$4.49M1.49%-40,100
FREELINE THERAPEUTICS HLDGSFREELINE THERAPEUTICS HLDGSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 1,876,389 shares 1,876,389$3.71M1.23%+448,908
G1 THERAPEUTICS INCG1 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 230,000 shares 230,000$2.35M0.78%+180,000
OVIDOVID THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 400,000 shares 400,000$1.28M0.43%+166,490Timeline
KROSKEROS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 17,518 shares 17,518$1.02M0.34%+4,891Timeline
CRVSCORVUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: restricted; 2021Q1: restricted; 2021Q2: restricted; 2021Q3: restricted; 2021Q4: 400,000 shares 400,000$964K0.32%+234,073Timeline

How Q4 2021 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001085146-22-000838 base2022-02-11acceptance time not in the bulk data set